Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
ACS Sens ; 6(9): 3468-3476, 2021 09 24.
Article in English | MEDLINE | ID: covidwho-1392782

ABSTRACT

This research reveals the promising functionalization of graphene oxide (GrO)-glazed double-interdigitated capacitive (DIDC) biosensing platform to detect severe acute respiratory syndrome coronavirus (SARS-CoV-2) spike (S1) proteins with enhanced selectivity and rapid response. The DIDC bioactive surface consisting of Pt/Ti featured SiO2 substrate was fabricated using GrO/EDC-NHS/anti-SARS-CoV-2 antibodies (Abs) which is having layer-by-layer interface self-assembly chemistry method. This electroactive immune-sensing platform exhibits reproducibility and sensitivity with reference to the S1 protein of SARS-CoV-2. The outcomes of analytical studies confirm that GrO provided a desired engineered surface for Abs immobilization and amplified capacitance to achieve a wide detection range (1.0 mg/mL to 1.0 fg/mL), low limit of detection (1 fg/mL) within 3 s of response time, good linearity (18.56 nF/g), and a high sensitivity of 1.0 fg/mL. Importantly, the unique biochip was selective against blood-borne antigens and standby for 10 days at 5 °C. Our developed DIDC-based SARS-CoV-2 biosensor is suitable for point-of-care (POC) diagnostic applications due to portability and scaling-up ability. In addition, this sensing platform can be modified for the early diagnosis of severe viral infections using real samples.


Subject(s)
COVID-19 , SARS-CoV-2 , Graphite , Humans , Reproducibility of Results , Silicon Dioxide , Spike Glycoprotein, Coronavirus
2.
Biosens Bioelectron ; 185: 113177, 2021 Aug 01.
Article in English | MEDLINE | ID: covidwho-1206999

ABSTRACT

Rapid diagnosis and case isolation are pivotal to controlling the current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this study, a label-free DNA capacitive biosensor for the detection of SARS-CoV-2 that demonstrates real-time, low-cost, and high-throughput screening of nucleic acid samples is presented. Our novel biosensor composed of the interdigitated platinum/titanium electrodes on the glass substrate can detect the hybridization of analyte DNA with probe DNA. The hybridization signals of specific DNA sequences were verified through exhaustive physicochemical analytical techniques such as Fourier transform infrared (FT-IR) spectrometry, contact-angle analysis, and capacitance-frequency measurements. For a single-step hybridized reaction, the fabricated kit exhibited significant sensitivity (capacitance change, ΔC = ~2 nF) in detecting the conserved region of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) gene with high sensitivity of 0.843 nF/nM. In addition to capacitive measurements, this selective detection was confirmed by the fluorescence image and intensity from a SARS-CoV-2 gene labeled with a fluorescent dye. We also demonstrated that the kits are recyclable by surface ozone treatment using UV irradiation. Thus, these kits could potentially be applied to various types of label-free DNA, thereby acting as rapid, cost-effective biosensors for several diseases.


Subject(s)
Biosensing Techniques , COVID-19 , DNA , Humans , Point-of-Care Systems , RNA, Viral , SARS-CoV-2 , Sensitivity and Specificity , Spectroscopy, Fourier Transform Infrared
3.
Int J Nanomedicine ; 16: 539-560, 2021.
Article in English | MEDLINE | ID: covidwho-1058334

ABSTRACT

The newly emerged ribonucleic acid (RNA) enveloped human beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection caused the COVID-19 pandemic, severely affects the respiratory system, and may lead to death. Lacking effective diagnostics and therapies made this pandemic challenging to manage since the SARS-CoV-2 transmits via human-to-human, enters via ACE2 and TMPSSR2 receptors, and damages organs rich in host cells, spreads via symptomatic carriers and is prominent in an immune-compromised population. New SARS-CoV-2 informatics (structure, strains, like-cycles, functional sites) motivated bio-pharma experts to investigate novel therapeutic agents that act to recognize, inhibit, and knockdown combinations of drugs, vaccines, and antibodies, have been optimized to manage COVID-19. However, successful targeted delivery of these agents to avoid off-targeting and unnecessary drug ingestion is very challenging. To overcome these obstacles, this mini-review projects nanomedicine technology, a pharmacologically relevant cargo of size within 10 to 200 nm, for site-specific delivery of a therapeutic agent to recognize and eradicate the SARS-CoV-2, and improving the human immune system. Such combinational therapy based on compartmentalization controls the delivery and releases of a drug optimized based on patient genomic profile and medical history. Nanotechnology could help combat COVID-19 via various methods such as avoiding viral contamination and spraying by developing personal protective equipment (PPE) to increase the protection of healthcare workers and produce effective antiviral disinfectants surface coatings capable of inactivating and preventing the virus from spreading. To quickly recognize the infection or immunological response, design highly accurate and sensitive nano-based sensors. Development of new drugs with improved activity, reduced toxicity, and sustained release to the lungs, as well as tissue targets; and development of nano-based immunizations to improve humoral and cellular immune responses. The desired and controlled features of suggested personalized therapeutics, nanomedicine, is a potential therapy to manage COVID-19 successfully. The state-of-the-art nanomedicine, challenges, and prospects of nanomedicine are carefully and critically discussed in this report, which may serve as a key platform for scholars to investigate the role of nanomedicine for higher efficacy to manage the COVID-19 pandemic.


Subject(s)
COVID-19/therapy , COVID-19/virology , Nanomedicine/trends , SARS-CoV-2/physiology , Animals , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , COVID-19/epidemiology , COVID-19/prevention & control , Humans , Nanotechnology , Pandemics/prevention & control , SARS-CoV-2/drug effects
4.
ACS Appl Bio Mater ; 3(11): 7306-7325, 2020 11 16.
Article in English | MEDLINE | ID: covidwho-889126

ABSTRACT

To manage the COVID-19 pandemic, development of rapid, selective, sensitive diagnostic systems for early stage ß-coronavirus severe acute respiratory syndrome (SARS-CoV-2) virus protein detection is emerging as a necessary response to generate the bioinformatics needed for efficient smart diagnostics, optimization of therapy, and investigation of therapies of higher efficacy. The urgent need for such diagnostic systems is recommended by experts in order to achieve the mass and targeted SARS-CoV-2 detection required to manage the COVID-19 pandemic through the understanding of infection progression and timely therapy decisions. To achieve these tasks, there is a scope for developing smart sensors to rapidly and selectively detect SARS-CoV-2 protein at the picomolar level. COVID-19 infection, due to human-to-human transmission, demands diagnostics at the point-of-care (POC) without the need of experienced labor and sophisticated laboratories. Keeping the above-mentioned considerations, we propose to explore the compartmentalization approach by designing and developing nanoenabled miniaturized electrochemical biosensors to detect SARS-CoV-2 virus at the site of the epidemic as the best way to manage the pandemic. Such COVID-19 diagnostics approach based on a POC sensing technology can be interfaced with the Internet of things and artificial intelligence (AI) techniques (such as machine learning and deep learning for diagnostics) for investigating useful informatics via data storage, sharing, and analytics. Keeping COVID-19 management related challenges and aspects under consideration, our work in this review presents a collective approach involving electrochemical SARS-CoV-2 biosensing supported by AI to generate the bioinformatics needed for early stage COVID-19 diagnosis, correlation of viral load with pathogenesis, understanding of pandemic progression, therapy optimization, POC diagnostics, and diseases management in a personalized manner.


Subject(s)
Artificial Intelligence , COVID-19/therapy , Electrochemical Techniques/methods , Point-of-Care Systems , COVID-19/epidemiology , COVID-19/virology , Humans , Pandemics , SARS-CoV-2/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL